The study supports prior research that found the same thing.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...